Daniela Ernst

Human genetic disorders of sphingolipid biosynthesis

Sphingolipid metabolism in cancer signalling and therapy

Sphingolipids and their metabolism in physiology and disease

Many Ceramides

Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study

Unraveling the role of the Target of Rapamycin signaling in sphingolipid metabolism

HSAN1 mutations in serine palmitoyltransferase reveal a close structure–function–phenotype relationship

Tackling the biophysical properties of sphingolipids to decipher their biological roles

Exosomes

Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency

Sphingolipids in High Fat Diet and Obesity‐Related Diseases

Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus

Elevation of 20-carbon long chain bases due to a mutation in serine palmitoyltransferase small subunit b results in neurodegeneration

Novel HSAN1 Mutation in Serine Palmitoyltransferase Resides at a Putative Phosphorylation Site That Is Involved in Regulating Substrate Specificity

Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?

The SPTLC3 Subunit of Serine Palmitoyltransferase Generates Short Chain Sphingoid Bases

Hereditary sensory and autonomic neuropathy type 1 (HSANI) caused by a novel mutation in SPTLC2

Neurotoxic 1‐deoxysphingolipids and paclitaxel‐induced peripheral neuropathy